Literature DB >> 5448781

Trimethoprim-sulphamethoxazole in acute osteomyelitis due to penicillin-resistant staphylococci in Uganda.

J L Craven, D J Pugsley, R Blowers.   

Abstract

Most recent cases of staphylococcal osteomyelitis seen at Mulago Hospital, Kampala, have been due to penicillin-resistant organisms. Six severely ill patients-four with multiple bone lesions-were treated with trimethoprim-sulphamethoxazole; the response was prompt and satisfactory in all cases.

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5448781      PMCID： PMC1701141          DOI： 10.1136/bmj.3.5716.201

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  2 in total

1.  Combined treatment with antibacterial chemotherapeutical agents in staphylococcal infections.

Authors:  K Jensen; H C Lassen
Journal:  Q J Med       Date:  1969-01

2.  Trimethoprim: laboratory and clinical studies.

Authors:  J H Darrell; L P Garrod; P M Waterworth
Journal:  J Clin Pathol       Date:  1968-03       Impact factor: 3.411
  2 in total
  6 in total

1.  Sulphamethoxazole-trimethoprim: the first two years.

Authors:  D S Reeves
Journal:  J Clin Pathol       Date:  1971-07       Impact factor: 3.411

Review 2.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

3.  Acute haematogenous osteitis.

Authors:  J R Anderson; J D Orr; D A Maclean; W G Scobie
Journal:  Arch Dis Child       Date:  1980-12       Impact factor: 3.791

Review 4.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

5.  Resistance of Staphylococcus aureus to sulphamethoxazole and trimethoprim.

Authors:  L S Nakhla
Journal:  J Clin Pathol       Date:  1972-08       Impact factor: 3.411

6.  Efficacy of cotrimoxazole (Sulfamethoxazole-Trimethoprim) as a salvage therapy for the treatment of bone and joint infections (BJIs).

Authors:  Laurene Deconinck; Aurélien Dinh; Christophe Nich; Thomas Tritz; Morgan Matt; Olivia Senard; Simon Bessis; Thomas Bauer; Martin Rottman; Jérome Salomon; Frédérique Bouchand; Benjamin Davido
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.